Discovery of highly selective and orally available benzimidazole-based phosphodiesterase 10 inhibitors with improved solubility and pharmacokinetic properties for treatment of pulmonary arterial hypertension

Yuncong Yang,Sirui Zhang,Qian Zhou,Chen Zhang,Yuqi Gao,Hao Wang,Zhe Li,Deyan Wu,Yinuo Wu,Yi-You Huang,Lei Guo,Hai-Bin Luo

DOI: https://doi.org/10.1016/j.apsb.2020.04.003

IF: 14.903

2020-12-01

Acta Pharmaceutica Sinica B

Abstract:<p>Optimization efforts were devoted to discover novel PDE10A inhibitors in order to improve solubility and pharmacokinetics properties for a long-term therapy against pulmonary arterial hypertension (PAH) starting from the previously synthesized inhibitor <strong>A</strong>. As a result, a potent and highly selective PDE10A inhibitor, <strong>14·</strong>3HCl (half maximal inhibitory concentration, IC₅₀=2.8 nmol/L and <em>&gt;</em>3500-folds selectivity) exhibiting desirable solubility and metabolic stability with a remarkable bioavailability of 50% was identified with the aid of efficient methods of binding free energy predictions. Animal PAH studies showed that the improvement offered by <strong>14·</strong>3HCl [2.5 mg/kg, oral administration (<em>p.o</em>.)] was comparable to tadalafil (5.0 mg/kg, <em>p.o</em>.), verifying the feasibility of PDE10A inhibitors for the anti-PAH treatment. The crystal structure of the PDE10A−<strong>14</strong> complex illustrates their binding pattern, which provided a guideline for rational design of highly selective PDE10A inhibitors.</p>

pharmacology & pharmacy